The Inova Type 2 Diabetes Mellitus Study

Withdrawn before enrolling · Not applicable

Conditions studied: Diabetes, Type 2

In brief

The purpose of this study is to compare the safety and effectiveness of the two different basal insulins commonly used for basal blood sugar control in the treatment of type 2 diabetes mellitus in patients who are hospitalized and require low doses of insulin: neutral protamine Hagedorn (NPH) insulin and glargine (Lantus®) insulin. Previous research has shown that both NPH insulin and glargine (Lantus®) insulin is safe and effective for the control of blood sugar in a type 2 diabetic patient. This research is being done because the costs of medications for diabetic patients are very expensive. Our goal with this research is to show that a less expensive insulin (NPH) is as safe and effective as a more expensive insulin \[glargine (Lantus®)\] in patients with type 2 diabetes mellitus who are in the hospital.

Key facts

Study ID

NCT02222623

Run by

Inova Health Care Services

People needed

0

Starts

2015-04-01

Expected to finish

2016-05-01

Last updated by the study team

2016-08-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients ages18-75 admitted to a general medicine or surgical Department of Medicine hospitalist services.
• A known history of T2DM, receiving either diet alone, low dose insulin (≤0.4 units/kg/day), OADs, GLP1 analogs, or in any combination of OADs, GLP1 analogs and low dose insulin (≤0.4 units/kg/day).
• Subjects must have a BG >140 mg/dL and ≤240 mg/dL before randomization without laboratory evidence of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic syndrome (bicarbonate <18 mEq/L, pH <7.30, or positive serum or urinary ketones, BG >240 mg/dL).

You may not qualify if…

• Patients with a diagnosis of type 1 diabetes mellitus.
• Patients using nutritional bolus insulin at home.
• Patients with increased blood glucose concentration, but without a known history of diabetes.
• Patients with a history of diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic syndrome, or ketonuria.
• Patients admitted to or expected to require admission to any intensive care unit (ICU) or intermediate care unit (IMC).
• Patients who are receiving or are anticipated to receive enteral or parenteral nutrition.
• Patients admitted for cardiac surgery.
• Patients receiving continuous insulin infusion.
• Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, or impaired renal function (creatinine ≥ 3.5 mg/dL).
• Persons with decisional incapacity (mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study).
• Female subjects who are pregnant or immediately (same hospitalization) post partum at time of enrollment into the study.
• Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism.

Where it is running

• Inova Fairfax Hospital — Falls Church, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.